Conference Roundup

ASH: Novel Fetal Hemoglobin Repressor for Sickle Cell Disease Identified

Posted on

Syros Pharmaceuticals a leader in the development of medicines that control the expression of genes, today announced that it has discovered and validated a novel fetal hemoglobin repressor, Nuclear Factor I X (NFIX), using its gene control platform. The finding sheds light on how the gamma-globin gene, which leads to the production of fetal hemoglobin, is controlled and points to new potential targets for therapeutic intervention in sickle cell disease. These data will be presented in an oral presentation tomorrow at the 61st American Society of Hematology (ASH) Annual Meeting and were highlighted today in an ASH press briefing.

Read the full press release here.

Source: Syros Pharmaceuticals, Inc
Related Articles
Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment
Jun 01, 2021
Education and Support Enhance Care for Rare-Disease Patients
Mar 27, 2020
Efgartigimod Safe, Effective in Primary Immune Thrombocytopenia
Mar 20, 2020